Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Disaggregated Research and Development Expenses and Segment Net Loss

In addition to the significant expense categories included on the Company's consolidated statements of operations, refer below for disaggregated amounts that comprise research and development expenses and the segment net loss (in thousands):


	For the three months ended June 30,						For the six months ended June 30,
	2026			2025			2026			2025
Operating expenses:
Research and development operating costs expenses excluding non-cash stock-based compensation:
Primary program research and development expenses (a)	$	15,919		$	16,708		$	31,907		$	31,447
Other research and development expenses:
Payroll and benefits		3,384			3,210			6,619			6,098
Occupancy and other overhead and operating costs		566			448			1,201			1,074
Total other research and development expenses		3,950			3,658			7,820			7,172
Research and development operating expenses excluding non-cash stock-based compensation:		19,869			20,366			39,727			38,619
General and administrative expense excluding non-cash stock-based compensation		13,303			8,371			21,684			15,551
Other segment income (expense), net (b)		7,056			1,664			16,101			2,870
Segment net loss	$	(40,228	)	$	(30,401	)	$	(77,512	)	$	(57,040	)

Primary program research and development expenses are comprised primarily of costs paid to third parties for clinical trials and product development manufacturing, nonclinical, regulatory, and quality assurance activities, and the portion of related research and development expenses incurred by our collaborators and third-party service providers, including contract research and manufacturing organizations that we are obligated to reimburse.

Other segment income (expense), net includes interest income, interest expense, foreign currency exchange gain or loss, depreciation and amortization, non-cash stock-based compensation, loss on extinguishment of debt (for the six months ended June 30, 2025), and tax credit income.